Sign in
CompletedNo phase

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study

Key facts

Who runs it
Spectral Diagnostics (US) Inc.
Where
Ann Arbor, Atlanta, Birmingham, Boulder, Camden, Charleston, Chattanooga, Houston, Little Rock, New York, Piscataway, Pittsburgh, Rochester, San Antonio, San Francisco, Shreveport, Springfield, Stony Brook, and Washington D.C., United StatesSee the 20 sites
Trial code
Status
Completed
People taking part
157 people enrolled
Started
9 Jan 2020
Ended
10 Feb 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
Record updated
13 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Age ≥18 years of age
  • Hypotension requiring vasopressor support: Requirement for at least one of the vasopressors listed below, at the dose shown below, for at least 2 continuous hours and no more than 30 hours; Norepinephrine > 0.05mcg/kg/min; Dopamine > 10 mcg/kg/min; Phenylephrine > 0.4 mcg/kg/min; Epinephrine > 0.05 mcg/kg/min; Vasopressin > 0.03 units/min; Vasopressin (any dose) in combination with another vasopressor listed above
  • The subject must have received intravenous fluid resuscitation of a minimum of 30mL/kg administered within 24 hours of eligibility
  • Documented or suspected infection defined as definitive or empiric intravenous antibiotic administration
  • The subject must have a screening multi-organ dysfunction score (MODS) >9 OR a sequential organ failure assessment (SOFA) >11, in the event a complete MODS cannot be obtained due to missing measurements
  • Endotoxin Activity Assay between ≥ 0.60 to <0.90 EA units
  • Evidence of at least 1 of the following criteria for new onset organ dysfunction that is considered to be due to the acute illness:; Requirement for positive pressure ventilation via an endotracheal tube or tracheostomy tube; Thrombocytopenia defined as acute onset of platelet count <150,000µ/L or a reduction of 50% from prior known levels; Acute oliguria defined as urine output <0.5mL/kg/hr for at least 6 hours despite adequate fluid resuscitation

Who cannot take part

  • Inability to achieve or maintain a minimum mean arterial pressure (MAP) of ≥ 65mmHg despite vasopressor therapy and fluid resuscitation
  • Subject is currently enrolled in an investigational drug or device trial
  • Subject has been previously enrolled in the current trial
  • Subject has end-stage renal disease and requires chronic dialysis
  • Subject has had an acute myocardial infarction (AMI) within the past 4 weeks
  • Subject has uncontrolled hemorrhage (acute blood loss requiring > 3 UPC in the past 24 hours)
  • Known hypersensitivity to Polymyxin B
  • Subject has known sensitivity or allergy to heparin or has a history of heparin associated thrombocytopenia (H.I.T.)
  • Any other condition, that in the opinion of the investigator, would preclude the subject from being a suitable candidate for enrollment, such as end-stage chronic illness (eg. lack of source control and bowel necrosis) with no reasonable expectation of survival to hospital discharge
  • There is clinical support for non-septic shock such as:; Acute pulmonary embolus; Transfusion reaction; Severe congestive heart failure (e.g. NYHA Class IV, ejection fraction < 35%)
  • Subject has severe granulocytopenia (leukocyte count less than 500 cells/mm3) or severe thrombocytopenia (platelet count less than 30,000 cells/mm3)
  • HIV infection in association with a last known or suspected CD4 count of <50/mm3
  • Inability to obtain an informed consent from the subject, family member or an authorized surrogate
  • Lack of commitment for full medical support
  • Subject has had chest compressions as part of CPR during this hospitalization without immediate return to communicative state
  • Major trauma within 36 hours of screening
  • Subject's baseline state is non-communicative
  • Subject has sustained extensive third-degree burns within the past 7 days
  • Body weight < 35 kg (77 pounds)

Where in United States

  • University of MichiganAnn Arbor, United States
  • Emory UniversityAtlanta, United States
  • University of Alabama at BirminghamBirmingham, United States
  • Pulmonary AssociatesBoulder, United States
  • Cooper Health SystemCamden, United States
  • Medical University of South CarolinaCharleston, United States
  • CHI MemorialChattanooga, United States
  • Parkridge HospitalChattanooga, United States
  • The University of Texas Health Science Center at HoustonHouston, United States
  • University of Arkansas for Medical SciencesLittle Rock, United States
  • Mt Sinai HospitalNew York, United States
  • Rutgers, the State University of New JerseyPiscataway, United States
  • UPMCPittsburgh, United States
  • Mayo ClinicRochester, United States
  • Institute for Extracorporeal Life SupportSan Antonio, United States
  • University of California San FranciscoSan Francisco, United States
  • Louisiana State University Health ShreveportShreveport, United States
  • Baystate Medical CenterSpringfield, United States
  • Stony Brook UniversityStony Brook, United States
  • George Washington UniversityWashington D.C., United States

About the trial

What the trial wants to find out

Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock

The 2 groups in the trial

  • PMX TreatmentTreatment being tested

    Standard medical care for septic shock plus treatment with the PMX cartridge (twice approximately 24 hours apart)

    Treatment: Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge

  • ControlNo study treatment, for comparison

    Standard medical care alone

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of PMX Cartridge in Addition to Standard Medical Care for Patients With Endotoxemic Septic Shock
Publications
Record updated
13 October 2026